To find compounds like small molecules, peptides, or RNAi that change the phenotype of a cell or an organism in a desirable way, phenotypic screening is a sort of screening used in biological research and drug development. To understand how a phenotypic hit functions, phenotypic screening must be followed by identification and confirmation, frequently using chemoproteomics. Historically, medication discovery has been based on phenotypic screening. Compounds are tested in cellular or animal illness models to find those that result in a desired change in phenotype. The procedure of target deconvolution is used to identify the biological targets of chemicals only after they have been found. This comprehensive plan is known as target deconvolution. This overall strategy is referred to as "classical pharmacology", "forward pharmacology" or "phenotypic drug discovery" (PDD).
Title : Gamification and enabling technologies in preventative healthcare
David John Wortley, International Society of Digital Medicine (ISDM), United Kingdom
Title : Aidiet intervention vs. Hormonal and immune-metabolic health in normal and overweight adolescent girls with polycystic ovary syndrome
Malgorzata Mizgier, Poznan University of Physical Education, Poland
Title : Migration: A major challenge to health and safety at work
Mark Fullemann, Practice & Experience GmbH, Switzerland
Title : Principles and standards for designing and managing intelligent and ethical health and social care ecosystems
Habil Bernd Blobel, University of Regensburg, Germany
Title : Trends in the epigenetics human longevity: Sorting hope from hype
Kenneth R Pelletier, University of California, United States
Title : Occupational health and safety of Hong Kong nursing students during clinical placement: A study tool development
Wong Yat Cheung Maggie, Saint Francis University, Hong Kong